CTSO (CytoSorbents) Institutional Ownership: 25.42% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTSO CytoSorbents Corp CTSO
31 GF Score
Price $0.40
GF Value $0.86
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CytoSorbents Institutional Ownership?

CytoSorbents CTSO +10.38% 31 Institutional Ownership is 25.42% as of Aug. 16, 2026. GuruFocus rates CTSO with a GF Score™ of 31/100 and a GF Value™ of $0.86 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytoSorbents's institutional ownership is 25.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytoSorbents's Insider Ownership is 36.57%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytoSorbents's Float Percentage Of Total Shares Outstanding is 92.16%.

CytoSorbents Institutional Ownership Historical Data

* Premium members only.

The historical data trend for CytoSorbents's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoSorbents Institutional Ownership Chart

CytoSorbents Historical Data

The historical data trend for CytoSorbents can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 7.86 7.86 7.17 7.20 7.19 7.39 7.35 7.33 6.97 6.95
CTSO
31GF Score
CytoSorbents Corp CTSO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoSorbents Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 25.42% mean?
CytoSorbents (CTSO) has a Institutional Ownership of 25.42% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CytoSorbents and its competitors.
Is CytoSorbents' Institutional Ownership too high?
CytoSorbents' current Institutional Ownership is 25.42%. Overall, CytoSorbents has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Institutional Ownership compare to GTHP and LFWD?
CytoSorbents' Institutional Ownership of 25.42% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CytoSorbents and its competitors. CytoSorbents's current Institutional Ownership is 25.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
Based on GuruFocus' analysis, CytoSorbents (CTSO) is currently considered Possible Value Trap. The stock's GF Value™ is $0.86, compared to a current price of $0.40 — trading 53.5% below its estimated fair value. The current Institutional Ownership is 25.42%. CytoSorbents' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For CytoSorbents (CTSO), the current Institutional Ownership is 25.42% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytoSorbents (CTSO) Overvalued in 2026?

Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued. The current stock price of $0.40 is trading 53.5% below its estimated GF Value™ of $0.86. GuruFocus considers CytoSorbents to be Possible Value Trap.

Key valuation signals for CTSO:

  • Institutional Ownership: 25.42%
  • GF Value™: $0.86 vs. price of $0.40 (53.5% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the CTSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytoSorbents Business Description

Other Exchanges HQE1:Germany
Address 305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
31GF Score

Get the complete analysis for CTSO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.86
GF Value